K Asadullah

Summary

Affiliation: Schering AG
Country: Germany

Publications

  1. ncbi request reprint [New developments in the systemic treatment of psoriasis]
    Markus Friedrich
    Psoriasis Studienzentrum, Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Charite, Schumannstr 20 21, 10117 Berlin, Germany
    J Dtsch Dermatol Ges 1:12-21. 2003
  2. ncbi request reprint Cytokines: interleukin and interferon therapy in dermatology
    K Asadullah
    Schering AG, Berlin, Germany
    Clin Exp Dermatol 27:578-84. 2002
  3. ncbi request reprint Cytokine therapy in dermatology
    K Asadullah
    Research Business Area Dermatology, A G Schering, D 13342 Berlin, Germany
    Exp Dermatol 11:97-106. 2002
  4. ncbi request reprint Interleukin-10 therapy--review of a new approach
    K Asadullah
    Head of Corporate Research Business Area Dermatology, Schering AG, D 13342 Berlin, Germany
    Pharmacol Rev 55:241-69. 2003
  5. ncbi request reprint Analysis of cytokine expression in dermatology
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, Mullerstrasse 178, D 13342 Berlin, Germany
    Arch Dermatol 138:1189-96. 2002
  6. ncbi request reprint Novel immunotherapies for psoriasis
    Khusru Asadullah
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Trends Immunol 23:47-53. 2002
  7. ncbi request reprint Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, Berlin, Germany
    Curr Drug Targets Inflamm Allergy 3:185-92. 2004
  8. ncbi request reprint Interleukin-10 promoter polymorphism in psoriasis
    K Asadullah
    Department of Dermatology, Medical School Charite, Humboldt University Berlin, Berlin, Germany
    J Invest Dermatol 116:975-8. 2001
  9. ncbi request reprint Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings
    K Asadullah
    Institute of Medical Immunology and Department of Dermatology, University Hospital Charite, Berlin Humboldt University, Berlin, Germany
    J Invest Dermatol 116:721-7. 2001
  10. ncbi request reprint Experimental therapies for psoriasis
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, D 13342 Berlin, Germany
    Arch Immunol Ther Exp (Warsz) 50:411-20. 2002

Collaborators

Detail Information

Publications64

  1. ncbi request reprint [New developments in the systemic treatment of psoriasis]
    Markus Friedrich
    Psoriasis Studienzentrum, Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Charite, Schumannstr 20 21, 10117 Berlin, Germany
    J Dtsch Dermatol Ges 1:12-21. 2003
    ..Furthermore results of therapeutic experiments should contribute to a better understanding of the disease. As we learn which mechanisms are more or less important for the disease, we will be better able to plan intervention strategies...
  2. ncbi request reprint Cytokines: interleukin and interferon therapy in dermatology
    K Asadullah
    Schering AG, Berlin, Germany
    Clin Exp Dermatol 27:578-84. 2002
    ..The aim of this review is to give an overview on the current state of cytokine therapy in dermatology...
  3. ncbi request reprint Cytokine therapy in dermatology
    K Asadullah
    Research Business Area Dermatology, A G Schering, D 13342 Berlin, Germany
    Exp Dermatol 11:97-106. 2002
    ..The terminology and immunobiology of cytokines are also briefly discussed, since for a sensible interpretation of the relevant findings a basic knowledge of these biologically highly active messenger substances is essential...
  4. ncbi request reprint Interleukin-10 therapy--review of a new approach
    K Asadullah
    Head of Corporate Research Business Area Dermatology, Schering AG, D 13342 Berlin, Germany
    Pharmacol Rev 55:241-69. 2003
    ..The results are heterogeneous. They give new insight into the immunobiology of IL-10 and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target...
  5. ncbi request reprint Analysis of cytokine expression in dermatology
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, Mullerstrasse 178, D 13342 Berlin, Germany
    Arch Dermatol 138:1189-96. 2002
    ....
  6. ncbi request reprint Novel immunotherapies for psoriasis
    Khusru Asadullah
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Trends Immunol 23:47-53. 2002
    ..If psoriasis is considered as a visible model disease for T-cell-mediated disorders characterized by a type-1 cytokine pattern these recent findings might have a more general impact on the treatment of autoimmune disorders...
  7. ncbi request reprint Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, Berlin, Germany
    Curr Drug Targets Inflamm Allergy 3:185-92. 2004
    ..Further investigations, in particular multicenter, placebo-controlled, double blind trials are required to fully determine whether IL-10 application will become a successful antipsoriatic therapy...
  8. ncbi request reprint Interleukin-10 promoter polymorphism in psoriasis
    K Asadullah
    Department of Dermatology, Medical School Charite, Humboldt University Berlin, Berlin, Germany
    J Invest Dermatol 116:975-8. 2001
    ..85 (1.55--9.62)] more likely to have a psoriatic family background if they carried this interleukin10.G13 allele. These data suggest that the interleukin-10 locus contributes to the heritability of psoriasis susceptibility...
  9. ncbi request reprint Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings
    K Asadullah
    Institute of Medical Immunology and Department of Dermatology, University Hospital Charite, Berlin Humboldt University, Berlin, Germany
    J Invest Dermatol 116:721-7. 2001
    ..Our findings demonstrate considerable effects of systemic interleukin-10 application on the skin immune systems, which might contribute to the anti-psoriatic activity of interleukin-10...
  10. ncbi request reprint Experimental therapies for psoriasis
    Khusru Asadullah
    Corporate Research Business Area Dermatology, Schering AG, D 13342 Berlin, Germany
    Arch Immunol Ther Exp (Warsz) 50:411-20. 2002
    ..Here we review the rationale and the initial clinical data of these important recent experimental therapies...
  11. pmc Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type
    C Schoenbein
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    Clin Exp Immunol 151:306-16. 2008
    ..These results complement our knowledge further about the biological effects of IL-10 and may provide an explanation for the sustained immunodeficiency in cases of the persistent presence of systemic IL-10...
  12. ncbi request reprint Is there an interaction between interleukin-10 and interleukin-22?
    K Wolk
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, D 10117 Berlin, Germany
    Genes Immun 6:8-18. 2005
    ..However, IL-10R2 interacted with defined IL-10- and IL-22-derived peptides supporting the hypothesis that cytokine binding to its corresponding R1 chain creates a binding site on this cytokine for IL-10R2...
  13. doi request reprint Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines
    K Witte
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    Genes Immun 10:702-14. 2009
    ....
  14. ncbi request reprint The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes
    M Seifert
    Department of Medical Immunology, Medical School Charite, Humboldt University Berlin, Germany
    Arch Dermatol Res 292:164-72. 2000
    ..Finally, our results argue against the value of IL-10 therapy in dermatoses strictly limited to keratinocyte involvement...
  15. ncbi request reprint Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis
    W D Docke
    Institute of Medical Immunology, Department of Dermatology, University Hospital Charite, Berlin Humboldt University, D 10098 Berlin, Germany
    Br J Dermatol 148:954-63. 2003
    ..This, however, is of interest because of the high prevalence of latent infections in the general population, the frequent reactivation in inflammatory diseases, and the immunomodulating capacity of CMV...
  16. ncbi request reprint Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation
    C Woiciechowsky
    Department of Neurosurgery, Virchow Klinikum, Humboldt University Medical School, Berlin, Germany
    J Neuroimmunol 84:164-71. 1998
    ..The demonstrated severe glioblastoma-associated monocytic deactivation may contribute to its unfavorable prognosis. Therefore, monocytes may represent target cells for new adjuvant immunotherapies in glioblastoma...
  17. pmc IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach
    K Asadullah
    Department of Dermatology, University Hospital Charite, Berlin Humboldt University, D 10098 Berlin, Germany
    J Clin Invest 101:783-94. 1998
    ..Our investigations demonstrate the major importance of IL-10 in psoriasis and show that IL-10 administration represents a new therapeutic approach. This is the first report on IL-10 therapy for cutaneous disorders...
  18. doi request reprint Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy
    S Schoepe
    Common Mechanism Research Berlin, Berlin, Germany
    Skin Pharmacol Physiol 23:139-51. 2010
    ..Further experiments are necessary to eventually reduce this panel and to demonstrate the true predictability for the clinic...
  19. ncbi request reprint Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis
    P Hensen
    Department of Dermatology, University of Munster, Munster, Germany
    Br J Dermatol 149:381-5. 2003
    ..G) and in a recent case-control study the IL10.G13 (144 bp) allele was found to be associated with familial early onset psoriasis (type 1 psoriasis) having a susceptible effect...
  20. ncbi request reprint Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart
    B Weiss
    Enabling Technologies, Schering AG, Berlin, Germany
    Genes Immun 5:330-6. 2004
    ..Differential modulation of IL-22R alpha 2 mRNA expression was observed upon systemic inflammation in mice in spleen, thymus, and lymph node...
  21. pmc Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases
    H Schäcke
    Bayer Schering Pharma, Global Drug Discovery, Berlin, Germany
    Br J Pharmacol 158:1088-103. 2009
    ..Here we report on ZK 245186, a novel, non-steroidal, low-molecular-weight, glucocorticoid receptor-selective agonist for the topical treatment of inflammatory dermatoses...
  22. pmc Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50
    F Driessler
    Research Business Area Dermatology, Research Laboratories of Schering AG, Berlin, Germany
    Clin Exp Immunol 135:64-73. 2004
    ..Our findings suggest that the selective induction of nuclear translocation and DNA-binding of the repressive p50/p50 homodimer is an important anti-inflammatory mechanism utilized by IL-10 to repress inflammatory gene transcription...
  23. ncbi request reprint A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta
    B H Gruenberg
    Department of Experimental Dermatology, Schering AG, D 13342 Berlin, Germany
    Genes Immun 2:329-34. 2001
    ..The preferential expression of CRF2-s1 in placenta suggests a role for this receptor in establishing and maintaining successful pregnancy...
  24. ncbi request reprint Glucocorticoid therapy-induced skin atrophy
    Stefanie Schoepe
    Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Exp Dermatol 15:406-20. 2006
    ..New insights into GC modes of action will guide optimization strategies aiming at novel GC receptor ligands with improved effect/side effect profile...
  25. ncbi request reprint The immunological synapse: kinases in T cell signalling as potential drug targets
    Gottfried Baier
    Medical University of Innsbruck, Austria
    Immunol Lett 105:3-5. 2006
    ..g. asthma, rheumatoid arthritis, multiple sclerosis and transplant rejection)...
  26. ncbi request reprint Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis
    Robert P Numerof
    Research Business Area Dermatology USA, Berlex Biosciences, Richmond, California 94804 0099, USA
    BioDrugs 20:93-103. 2006
    ....
  27. ncbi request reprint IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis
    Kerstin Wolk
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    Eur J Immunol 36:1309-23. 2006
    ..In summary, despite similarities, IFN-gamma primarily amplifies inflammation, while IL-22 may be important in the innate immunity and reorganization of epithelia...
  28. ncbi request reprint Cytokines as potential therapeutic targets for inflammatory skin diseases
    Robert P Numerof
    RBA Dermatology USA, Berlex Biosciences, 2600 Hilltop Drive, PO Box 4099, Richmond, CA 94804 0099, USA
    Eur Cytokine Netw 16:101-3. 2005
    ..In this short review, we summarize key findings from a recent workshop on cytokines as potential therapeutic targets for inflammatory skin diseases...
  29. ncbi request reprint Efomycine M: an inhibitor of selectins?
    Arne von Bonin
    Nat Med 12:873; author reply 873-4. 2006
  30. ncbi request reprint Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs
    Stefanie Kunz
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    Exp Dermatol 15:991-1004. 2006
    ..In summary, these data support the notion that IL-19, IL-20 and IL-24 are distinct from classical ILs and constitute a separate subfamily of mediators within the IL-10 family...
  31. ncbi request reprint Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
    Heike Schäcke
    CRBA Inflammation, Corporate Research, Schering AG, Berlin, Germany
    Exp Dermatol 15:565-73. 2006
    ..Nevertheless, considerable improvement in the therapeutic action of glucocorticoid receptor ligands is being achieved through the use of key molecular targets for screening novel glucocorticoid receptor ligands...
  32. ncbi request reprint CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity
    Parham Mirshahpanah
    TRG Inflammation and Immunology, Bayer Schering Pharma AG, Berlin, Germany
    Exp Dermatol 17:30-4. 2008
    ..We conclude that blocking CCR4 and CCR10 simultaneously, or their ligands, should be beneficial in the treatment of T-cell-mediated skin diseases...
  33. ncbi request reprint Immunopathogenesis of psoriasis
    Robert Sabat
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    Exp Dermatol 16:779-98. 2007
    ..Our model helps to explain the varied effectiveness of the currently tested immune modulating therapies and may enable the prediction of the success of future therapies...
  34. ncbi request reprint Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate
    Parham Mirshahpanah
    Research Business Area Dermatology, Berlex Biosciences, Richmond, CA, USA
    Exp Dermatol 16:753-61. 2007
    ..The degree to which this observation may translate into a clinical setting requires confirmation...
  35. ncbi request reprint Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index
    Heike Schäcke
    Bayer Schering Pharma AG, Global Drug Discovery, TRG Inflammation Immunology, Müllerstr 178, 13342 Berlin, Germany
    Mol Cell Endocrinol 275:109-17. 2007
    ..Such selective GR agonists (SEGRAs) are likely to enter clinical testing soon...
  36. ncbi request reprint Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells
    Joanna Listopad
    TRG Inflammation and Immunology, Bayer Schering Pharma AG, D 13442 Berlin, Germany
    Exp Dermatol 16:661-70. 2007
    ..Suppression of antigen-presenting cells may represent a main anti-inflammatory mechanism of HO-1...
  37. ncbi request reprint IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease
    Kerstin Wolk
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, Campus Charite Mitte, University Hospital Charite, Chariteplatz 1, Berlin, Germany
    J Immunol 178:5973-81. 2007
    ..These data suggest that systemic IL-22 may contribute to the prevention of systemic inflammation provoked by LPS present in the blood of CD patients through its induction of hepatic LBP...
  38. ncbi request reprint Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1
    Joachim C U Lehmann
    CRBA Inflammation, Schering AG, Berlin, Germany
    J Invest Dermatol 127:835-45. 2007
    ....
  39. ncbi request reprint Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index
    Heike Schäcke
    Schering AG, RBA Dermatology Europe, 13342 Berlin, Germany
    Curr Opin Investig Drugs 6:503-7. 2005
    ..Compounds that preferentially induce transrepression rather than transactivation should be superior to classical glucocorticoids. Indeed, proof of concept has been recently achieved with such selective glucocorticoid receptor agonists...
  40. ncbi request reprint Dimethylfumarate for psoriasis: more than a dietary curiosity
    Ulrich Mrowietz
    Department of Dermatology, University Clinic of Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Trends Mol Med 11:43-8. 2005
    ..Recent evidence also shows that these effects are mediated through the interference of the intracellular redox system by DMF. Here, the mode of action of FAE and its clinical use for psoriasis will be discussed...
  41. ncbi request reprint Dichotomy of glucocorticoid action in the immune system
    Khusru Asadullah
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Trends Immunol 23:120-2. 2002
  42. ncbi request reprint Cytokine and anticytokine therapy in dermatology
    Uwe Trefzer
    Department of Dermatology and Allergy, University Hospital Charite, Berlin Humboldt University, Berlin, Germany
    Expert Opin Biol Ther 3:733-43. 2003
    ..In this review, the current status of cytokine and anticytokine therapy for skin diseases is discussed...
  43. ncbi request reprint Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression
    Martina Seifert
    Institute of Medical Immunology, Medical School Charite, Humboldt University Berlin, Berlin, Germany
    Exp Dermatol 12:137-44. 2003
    ..Our data indicates that IL-10 unresponsiveness of keratinocytes could be explained by the lacking of functional IL-10 receptor expression and suggest that any IL-10 effects on these cells observed are indirectly mediated...
  44. ncbi request reprint Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity
    Arndt J Schottelius
    Institute of Medical Immunology, University Hospital Charite, Humboldt University Berlin, Schumannstrasse 20 21, D 10117 Berlin, Germany
    Trends Immunol 24:101-4. 2003
  45. ncbi request reprint A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity
    Ulrich Zugel
    Research Business Area DermatologyMedicinal Chemistry and Center of Dermatology, Schering AG, 13342 Berlin, Germany
    J Invest Dermatol 119:1434-42. 2002
    ..ZK 191784 is the first representative of a novel class of vitamin D analogs that might have therapeutic potential in T cell-mediated immune disorders...
  46. ncbi request reprint An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile
    Arndt J Schottelius
    Research Business Area Dermatology, Research Laboratories, Schering AG, Berlin, Germany
    J Immunol 169:7063-70. 2002
    ..Moreover, these results suggest that ATLa and related LXA(4) analogs may have broad therapeutic potential in inflammatory disorders and could provide an alternative to corticosteroids in certain clinical settings...
  47. ncbi request reprint Mechanisms involved in the side effects of glucocorticoids
    Heike Schäcke
    Research Business Area Dermatology, Schering AG, D 13342, Berlin, Germany
    Pharmacol Ther 96:23-43. 2002
    ..The focus on the molecular aspects should be helpful in predicting the potential advantages of selective GR agonists in comparison to classical GCs...
  48. ncbi request reprint Cutting edge: immune cells as sources and targets of the IL-10 family members?
    Kerstin Wolk
    Department of Experimental Dermatology, Schering AG, and Institute of Medical Immunology, Medical School Charite, Humboldt University, Berlin, Germany
    J Immunol 168:5397-402. 2002
    ..In these cells, IL-20R2 might be part of a still-unknown receptor complex. Therefore, immune cells may represent a major source but a minor target of the novel IL-10 family members...
  49. ncbi request reprint Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate
    Manfred Lehmann
    Institute of Medical Biochemistry and Molecular Biology, University of Rostock, Rostock, Germany
    Arch Dermatol Res 294:399-404. 2002
    ..This might have implications with regard to safety issues (e.g. immune monitoring) and novel potentially suitable indications (e.g. transplantation and other immune diseases)...
  50. ncbi request reprint Ultraviolet B radiation-mediated inhibition of interferon-gamma-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression
    Markus Friedrich
    Department for Dermatology and Allergology, Medical School Charite, Humboldt University Berlin, Berlin, Germany
    J Invest Dermatol 121:845-52. 2003
    ....
  51. ncbi request reprint Techniques: species' finest blend--humanized mouse models in inflammatory skin disease research
    Frederik H Igney
    Schering AG, CRBA Dermatology, Berlin, Germany
    Trends Pharmacol Sci 25:543-9. 2004
    ..So, how can mice be humanized, and how can humanized mice be employed in immunology research and drug discovery? In this article, we answer these questions, focusing on T-cell-mediated skin diseases as an example...
  52. ncbi request reprint IL-22 increases the innate immunity of tissues
    Kerstin Wolk
    Corporate Research Business Area Dermatology, Schering AG, D 13342 Berlin, Germany
    Immunity 21:241-54. 2004
    ..Taken together, IL-22 does not serve the communication between immune cells but is a T cell mediator that directly promotes the innate, nonspecific immunity of tissues...
  53. ncbi request reprint The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy
    Andrew C B Cato
    Forschungszentrum Karlsruhe, Institute of Toxicology and Genetics, P O Box 3640, D 76021 Karlsruhe, Germany
    Curr Drug Targets Inflamm Allergy 3:347-53. 2004
    ..These will provide invaluable source of information for the search of glucocorticoid receptor agonists with potent anti-inflammatory but reduced side effects...
  54. pmc Selectin and selectin ligand binding: a bittersweet attraction
    Thomas M Zollner
    Corporate Research Business Area Dermatology, Schering AG, Muellerstrasse 178, D 13342 Berlin, Germany
    J Clin Invest 112:980-3. 2003
    ....
  55. ncbi request reprint Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs
    Ekkehard May
    Corporate Research Business Area Dermatology, Schering AG, Mullerstrasse 178, D 13342 Berlin, Germany
    Curr Drug Targets Inflamm Allergy 3:377-93. 2004
    ..Its success might eventually lead to promising drugs for future therapeutic exploitation of a wide array of immune diseases, such as psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and others...
  56. ncbi request reprint Animal models of T-cell-mediated skin diseases
    Thomas M Zollner
    CRBA Dermatology, Schering AG, Berlin, Germany
    Bioessays 26:693-6. 2004
  57. ncbi request reprint Biology of tumor necrosis factor-alpha- implications for psoriasis
    Arndt J G Schottelius
    Schering AG Berlex Biosciences, Research Business Area Dermatology USA, Richmond, CA 94804 0099, USA
    Exp Dermatol 13:193-222. 2004
    ..In addition, the host-defense effects and chronic TNF-blocking activity are discussed...
  58. ncbi request reprint Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy
    Mechthild Jung
    Institute of Medical Immunology, Charite, Humboldt University Berlin, Berlin, Germany
    Eur J Immunol 34:481-93. 2004
    ..We could confirm a recently reported up-regulation of heme oxygenase-1 (HO-1). However, we demonstrate that the anti-inflammatory mechanisms of IL-10 remain functional even when HO-1 is irreversibly inhibited...
  59. pmc Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Heike Schäcke
    Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D 13342 Berlin, Germany
    Proc Natl Acad Sci U S A 101:227-32. 2004
    ..Moreover, they are useful tool compounds for further investigating the mechanisms of GR-mediated effects...
  60. ncbi request reprint Targeting leukocyte trafficking to inflamed skin: still an attractive therapeutic approach?
    Thomas M Zollner
    RBA Dermatology, Berlex Biosciences, Richmond, CA 94806, USA
    Exp Dermatol 16:1-12. 2007
    ..In this article, we delineate some pros and cons of this approach followed by a brief update on where we stand in the field and where we might move in the future...
  61. doi request reprint Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes
    Kerstin Wolk
    Interdisciplinary Group of Molecular Immunopathology, Dermatology Medical Immunology, University Hospital Charite, Berlin, Germany
    J Leukoc Biol 83:1181-93. 2008
    ..However, the strongest response to TLR2 and TLR3 activation showed keratinocytes in the simultaneous presence of IL-20 and IL-29...
  62. ncbi request reprint [Founding the new German Skin Research Center]
    Khusru Asadullah
    J Dtsch Dermatol Ges 5:1085-6. 2007
  63. ncbi request reprint Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis
    Markus Friedrich
    Department of Dermatology, University Hospital Charite, Berlin Humboldt University, Berlin, Germany
    J Invest Dermatol 118:672-7. 2002
    ..Its value should be further determined in larger trials and for the prevention of re-exacerbation of other inflammatory disorders with a similar immunologic profile...
  64. ncbi request reprint Nuclear receptors: old targets, new opportunities
    Khusru Asadullah
    Curr Drug Targets Inflamm Allergy 3:333-4. 2004